Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03635112
Registration number
NCT03635112
Ethics application status
Date submitted
31/07/2018
Date registered
17/08/2018
Date last updated
13/03/2023
Titles & IDs
Public title
Efficacy and Safety of TD-1473 in Crohn's Disease
Query!
Scientific title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo?Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease
Query!
Secondary ID [1]
0
0
2018-001272-37
Query!
Secondary ID [2]
0
0
0173
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DIONE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - TD-1473
Active Comparator: Active Treatment TD-1473 with Dose A - 1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.
Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
Active Comparator: Active Treatment TD-1473 with Dose B - 1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.
Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks.
Placebo Comparator: Placebo - 1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.
Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks.
Treatment: Drugs: Placebo
Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
Treatment: Drugs: TD-1473
TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Crohn's Disease Activity Index (CDAI) Score
Query!
Assessment method [1]
0
0
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease.
Query!
Timepoint [1]
0
0
Baseline to Week 12
Query!
Secondary outcome [1]
0
0
Number of Participants Who Demonstrated a Clinical Response as Measured by CDAI
Query!
Assessment method [1]
0
0
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease.
Clinical response was defined as a reduction from baseline of =100 points or CDAI <150
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Number of Participants Who Demonstrated CDAI Clinical Remission
Query!
Assessment method [2]
0
0
The CDAI score was generated using regression coefficients for eight different predictors of disease activity: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
Benchmarks for disease activity as measured by the CDAI were: <150, clinical remission; 150 to 219, mildly active disease; 220-450, moderately active disease; and >450, very severe disease.
CDAI clinical remission was defined as a CDAI score less than 150 at Week 12.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12
Query!
Assessment method [3]
0
0
The SES-CD incorporated 4 descriptors: the ulcer size, the proportion of surface covered by ulcer, the proportion of surface covered by other lesions, and the presence of stenosis. Each descriptor was scored in 5 segments (ileum, right colon, transverse colon, left colon, and rectum). The total score ranged from 0 to 56, with higher scores indicating a worse outcome.
Query!
Timepoint [3]
0
0
Baseline to Week 12
Query!
Secondary outcome [4]
0
0
Number of Participants With Endoscopic Response at Week 12
Query!
Assessment method [4]
0
0
Endoscopic Response was defined as a reduction of SES-CD score or Endoscopic Remission (defined as SES-CD = 2) at Week 12.
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Number of Participants With Stool Frequency and Abdominal Pain (SFAP) Clinical Remission
Query!
Assessment method [5]
0
0
SFAP clinical remission was defined as an abdominal pain score =1 (on a scale of 0-3 with 0 representing 'no pain' and 3 representing 'severe pain'), stool frequency =2.8, and both not worse than baseline at Week 12.
Query!
Timepoint [5]
0
0
Week 12
Query!
Eligibility
Key inclusion criteria
- Is at least 18 years of age at screening
- Males and females with clinical evidence of Crohn's disease for at least 3 months
duration at screening
- Moderately-to-severely active Crohn's Disease at baseline, as defined by a Crohn's
Disease Activity Index (CDAI) score of 220-450 inclusive
- SES-CD score of = 3 with ulceration (corresponding to a score of 1) in at least 1 of
the 5 ileocolonic segments on the Ulcerated Surface subscore of the SES-CD]
- Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to
conventional therapy (aminosalicylates, corticosteroids and immunomodulators such as
azathioprine, 6-mercaptopurine, or methotrexate) or biologics (e.g., anti-TNF therapy,
anti-IL-12/23 (anti-interleukin), anti-integrin).
- Additional inclusion criteria apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Is currently receiving biologic (anti-TNF, anti-integrin, or anti-IL12/23) therapy
- Has a current bacterial, parasitic, fungal, or viral infection
- Has clinically significant abnormalities in laboratory evaluations
- Prior exposure or potential exposure to a JAK inhibitor that was stopped due to
intolerance or lack of efficacy
- Subject has participated in another clinical trial of an investigational drug (or
medical device) within 30 days prior to Screening or 5x the half-life of the
investigational drug, whichever is longer, or is currently participating in another
trial of an investigational drug (or medical device)
- Subject has failed = 3 biologic agents of 3 different mechanisms of action (i.e.,
anti-TNF, anti-integrin, and anti-IL12/23)
- Additional exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/12/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
167
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,WA
Query!
Recruitment hospital [1]
0
0
Theravance Biopharma Investigational Site - Bankstown
Query!
Recruitment hospital [2]
0
0
Theravance Biopharma Investigational Site - Elizabeth Vale
Query!
Recruitment hospital [3]
0
0
Theravance Biopharma Investigational Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [3]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nevada
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oklahoma
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Carinthia
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Tyrol
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Vienna
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Sofiya
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Turgovishte
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Dobrich
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Plovdiv
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Sliven
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Stara Zagora
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Veliko Tarnovo
Query!
Country [30]
0
0
Croatia
Query!
State/province [30]
0
0
Osijek-baranja
Query!
Country [31]
0
0
Croatia
Query!
State/province [31]
0
0
Rijeka
Query!
Country [32]
0
0
Croatia
Query!
State/province [32]
0
0
Split
Query!
Country [33]
0
0
Croatia
Query!
State/province [33]
0
0
Zagreb
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Auvergne
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Champagne-ardenne
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Ile-de-france
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Midi-pyrenees
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Provence Alpes COTE D'azur
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rhone-alpes
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Clichy
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Vandœuvre-lès-Nancy
Query!
Country [42]
0
0
Georgia
Query!
State/province [42]
0
0
Tbilisi
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bayern
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Niedersachsen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Schleswig-holstein
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Berlin
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Hamburg
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Attica
Query!
Country [49]
0
0
Greece
Query!
State/province [49]
0
0
Crete
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Bacs-kiskun
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Hajdu-bihar
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Heves
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Budapest
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Rehoboth
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Sharon
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Haifa
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Holon
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Jerusalem
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Nahariya
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Petah Tikva
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Tel Aviv
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Gangwon-Do
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Gyeonggi-do
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Gyeonggi-Do
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Busan
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Daegu
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Seoul
Query!
Country [68]
0
0
New Zealand
Query!
State/province [68]
0
0
Waikato
Query!
Country [69]
0
0
New Zealand
Query!
State/province [69]
0
0
Wellington
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Dolnoslaskie
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Kujawsko-Pomorskie
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Lodzkie
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Malopolskie
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Masovian
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Mazowieckie
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Podkarpackie
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Pomorskie
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Slaskie
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Wielkopolskie
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Zachodnio-Pomorskie
Query!
Country [81]
0
0
Portugal
Query!
State/province [81]
0
0
Braga
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Guimarães
Query!
Country [83]
0
0
Portugal
Query!
State/province [83]
0
0
Leiria
Query!
Country [84]
0
0
Portugal
Query!
State/province [84]
0
0
Lisboa
Query!
Country [85]
0
0
Portugal
Query!
State/province [85]
0
0
Santa Maria da Feira
Query!
Country [86]
0
0
Portugal
Query!
State/province [86]
0
0
Setúbal
Query!
Country [87]
0
0
Portugal
Query!
State/province [87]
0
0
Vila Nova De Gaia
Query!
Country [88]
0
0
Romania
Query!
State/province [88]
0
0
Bihor
Query!
Country [89]
0
0
Romania
Query!
State/province [89]
0
0
Bucuresti
Query!
Country [90]
0
0
Romania
Query!
State/province [90]
0
0
Cluj
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Timis
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Moscow City
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Rostov
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Samarskaya Oblast
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Novosibirsk
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Saint Petersburg
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Saint-Petersburg
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Saratov
Query!
Country [99]
0
0
Serbia
Query!
State/province [99]
0
0
Belgrade
Query!
Country [100]
0
0
Serbia
Query!
State/province [100]
0
0
Kragujevac
Query!
Country [101]
0
0
Serbia
Query!
State/province [101]
0
0
Niš
Query!
Country [102]
0
0
Serbia
Query!
State/province [102]
0
0
Subotica
Query!
Country [103]
0
0
Serbia
Query!
State/province [103]
0
0
Zrenjanin
Query!
Country [104]
0
0
South Africa
Query!
State/province [104]
0
0
Gauteng
Query!
Country [105]
0
0
South Africa
Query!
State/province [105]
0
0
Western Cape
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Las Palmas
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Barcelona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Huelva
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Madrid
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Valencia
Query!
Country [111]
0
0
Ukraine
Query!
State/province [111]
0
0
Kiev City
Query!
Country [112]
0
0
Ukraine
Query!
State/province [112]
0
0
Kiev
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Poltava
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Transcarpathian
Query!
Country [115]
0
0
Ukraine
Query!
State/province [115]
0
0
Transcarpathia
Query!
Country [116]
0
0
Ukraine
Query!
State/province [116]
0
0
Chernivtsi
Query!
Country [117]
0
0
Ukraine
Query!
State/province [117]
0
0
Kharkiv
Query!
Country [118]
0
0
Ukraine
Query!
State/province [118]
0
0
Lviv
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Vinnytsia
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Zaporizhzhya
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
England
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Scotland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Theravance Biopharma
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with
moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03635112
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Theravance Biopharma
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03635112
Download to PDF